Thursday 03 Sep 2015

Hot Stocks On The Move: Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Celsion Corporation (NASDAQ:CLSN)

New York, NY – (NISMAGAZINE) – 5/09/2013- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) gained 3.73% at $0.835 after trading 405,843 shares. It is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Institutions own 17% of the company which has a market cap of $34.59 million. The stock traded the last 52 weeks in the range $0.37 – $2.27.

Is CPRX a solid investment at these levels? Get valuable insight and must-know updates here.

Celsion Corporation (NASDAQ:CLSN) plunged 7.91% at $0.930 after trading 5.04 million shares. Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology.  For the first quarter, the company declared EPS of -$0.12 which handily beat estimates by $0.04, and revenue of $125,000 which missed estimates by $65,000. The company also updated on its clinical trials of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin.  ThermoDox® is being evaluated in a global, multi-center Phase III clinical trial (the HEAT Study) in patients with non-resectable hepatocellular carcinoma (HCC), also known as primary liver cancer. Michael Tardugno, Celsion's President and Chief Executive Officer, said, “At this point, we have concluded that emerging findings from our post hoc analysis of the HEAT Study provide a basis for review with various regulatory agencies and an opportunity to discuss a path forward for our HCC development program.  Our recent expense reduction initiatives ensure a strong balance sheet as we explore opportunities to broaden our product pipeline and mitigate risk.”

How Should Investors Trade CLSN Now? Check out this exclusive report!


Subscribe for FREE to receive our “50 Stock Trading Rules No Hedge Fund Wants You To Know!” E-Book: continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.


Edmund Kaminski


Comments are closed.